$SENS
Senseonics Holdings, Inc. Stock $sens

$sens Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000155837021002458 Filed on March 05, 2021

Income Statement

Concept	2020 Q4	2020 Q3	2020 Q2
Revenue	$3.885M	$767.0K	$261.0K
YoY Change	-56.61%	-82.24%	-94.33%
Cost Of Revenue	$1.309M	-$68.00K	$1.404M
YoY Change	-92.39%	-100.89%	-84.67%
Gross Profit	$2.576M	$835.0K	-$1.143M
YoY Change	-131.25%	-125.0%	-74.9%
Gross Profit Margin	66.31%	108.87%	-437.93%
Selling, General & Admin	$8.195M	$8.735M	$7.587M
YoY Change	-51.48%	-48.46%	-61.28%
% of Gross Profit	318.13%	1046.11%
Research & Development		$4.568M	$3.796M
YoY Change		-58.76%	-63.86%
% of Gross Profit		547.07%
Depreciation & Amortization	$288.0K	$284.0K	$281.0K
YoY Change	-56.76%	-442.17%	28.9%
% of Gross Profit	11.18%	34.01%
Operating Expenses	$12.88M	$13.30M	$11.38M
YoY Change	-51.63%	-52.53%	-62.18%
Operating Profit	-$10.31M	-$12.47M	-$12.53M
YoY Change	-70.45%	-60.25%	-63.85%
Interest Expense	-$76.04M	$3.632M	$3.555M
YoY Change	8560.14%	-71.85%	6.63%
% of Operating Profit
Other Income/Expense, Net	-$12.30M	-$10.96M	$5.011M
YoY Change	-8639.58%	-192.37%	40.01%
Pretax Income	-$101.6M	-$23.43M	-$7.515M
YoY Change	185.39%	20.15%	-75.82%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$101.6M	-$23.43M	-$7.515M
YoY Change	185.39%	20.15%	-75.82%
Net Earnings / Revenue	-2616.01%	-3054.5%	-2879.31%
Basic Earnings Per Share		-$0.10
Diluted Earnings Per Share	-$405.1K	-$0.10	-$34.11K
COMMON SHARES
Basic Shares Outstanding	245.7M	236.5M
Diluted Shares Outstanding		236.5M

Balance Sheet

Concept	2020 Q4	2020 Q3	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.01M	$26.19M	$21.40M
YoY Change	-81.23%	-79.94%	-67.23%
Cash & Equivalents	$18.01M	$26.19M	$21.40M
Short-Term Investments	$0.00
Other Short-Term Assets	$3.974M	$4.788M	$5.888M
YoY Change	-11.92%	-1.52%	-3.33%
Inventory	$5.281M	$4.284M	$4.150M
Prepaid Expenses
Receivables	$2.986M	$501.0K	$670.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$30.25M	$35.77M	$32.11M
YoY Change	-76.33%	-77.86%	-65.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.557M	$1.665M	$1.771M
YoY Change	-22.19%	-68.9%	-58.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.886M	$4.224M	$4.245M
YoY Change
Other Assets	$101.0K	$2.409M	$2.716M
YoY Change	-96.68%	1890.91%	2221.37%
Total Long-Term Assets	$5.672M	$8.298M	$8.732M
YoY Change	12.47%	51.59%	97.56%
TOTAL ASSETS
Total Short-Term Assets	$30.25M	$35.77M	$32.11M
Total Long-Term Assets	$5.672M	$8.298M	$8.732M
Total Assets	$35.92M	$44.06M	$40.84M
YoY Change	-72.95%	-73.62%	-58.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.762M	$949.0K	$106.0K
YoY Change	-58.88%	-70.83%	-97.78%
Accrued Expenses	$11.52M	$9.100M	$12.13M
YoY Change	-38.05%	-51.23%	-34.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.202M	$0.00	$0.00
YoY Change	-96.91%		-100.0%
Total Short-Term Liabilities	$16.64M	$10.10M	$12.28M
YoY Change	-86.87%	-53.99%	-63.46%
LONG-TERM LIABILITIES
Long-Term Debt	$57.22M	$59.65M	$61.19M
YoY Change	384.88%	-33.94%	61.82%
Other Long-Term Liabilities	$1.483M	$1.693M	$1.895M
YoY Change	-34.9%	-94.25%	-83.95%
Total Long-Term Liabilities	$1.483M	$1.693M	$1.895M
YoY Change	-34.9%	-98.59%	-96.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.64M	$10.10M	$12.28M
Total Long-Term Liabilities	$1.483M	$1.693M	$1.895M
Total Liabilities	$177.2M	$96.03M	$80.44M
YoY Change	25.27%	-32.23%	-3.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$648.5M	-$546.9M	-$523.5M
YoY Change	37.01%
Common Stock	$266.0K	$244.0K	$231.0K
YoY Change	31.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$144.1M	-$54.78M	-$39.61M
YoY Change
Total Liabilities & Shareholders Equity	$35.92M	$44.06M	$40.84M
YoY Change	-72.95%	-73.62%	-58.5%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2020 Q2
OPERATING ACTIVITIES
Net Income	-$101.6M	-$23.43M	-$7.515M
YoY Change	185.39%	20.15%	-75.82%
Depreciation, Depletion And Amortization	$288.0K	$284.0K	$281.0K
YoY Change	-56.76%	-442.17%	28.9%
Cash From Operating Activities	-$8.248M	-$13.40M	-$16.73M
YoY Change	-76.13%	-62.4%	-53.14%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$3.000K	-$78.00K
YoY Change	-100.0%	-98.6%	-77.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$3.000K	-$78.00K
YoY Change	-100.0%	-98.6%	-68.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$100.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	61.00K	18.20M	19.60M
YoY Change	369.23%	-82.01%	-906.54%
NET CHANGE
Cash From Operating Activities	-8.248M	-13.40M	-16.73M
Cash From Investing Activities	0.000	-3.000K	-78.00K
Cash From Financing Activities	61.00K	18.20M	19.60M
Net Change In Cash	-8.187M	4.795M	2.792M
YoY Change	-76.37%	-92.66%	-107.27%
FREE CASH FLOW
Cash From Operating Activities	-$8.248M	-$13.40M	-$16.73M
Capital Expenditures	$0.00	-$3.000K	-$78.00K
Free Cash Flow	-$8.248M	-$13.39M	-$16.65M
YoY Change	-76.07%	-62.18%	-52.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001616543
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	sens:AccruedLiabilitiesAndOtherLiabilitiesCurrent
CY2019Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2019Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	203452812
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	265582688
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2018	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	0
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	sens:DepositsAndOtherAssetsNoncurrent
CY2019Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	sens:AccruedLiabilitiesAndOtherLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2020Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	sens:AccruedLiabilitiesAndOtherLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-37717
CY2020	dei	Entity Registrant Name EntityRegistrantName	SENSEONICS HOLDINGS, INC.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1210911
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	20451 Seneca Meadows Parkway
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Germantown
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20876-7005
CY2020	dei	City Area Code CityAreaCode	301
CY2020	dei	Local Phone Number LocalPhoneNumber	515-7260
CY2020	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2020	dei	Trading Symbol TradingSymbol	SENS
CY2020	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	74400000
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	377883267
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18005000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95938000
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	200000
CY2020Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	565000
CY2019Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	3239000
CY2020Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	2421000
CY2019Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	7140000
CY2020Q4	us-gaap	Inventory Net InventoryNet	5281000
CY2019Q4	us-gaap	Inventory Net InventoryNet	16929000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3774000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4512000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	30246000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	127758000
CY2020Q4	us-gaap	Derivative Assets Noncurrent DerivativeAssetsNoncurrent	1886000
CY2020Q4	sens	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	2229000
CY2019Q4	sens	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	3042000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1557000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2001000
CY2020Q4	us-gaap	Assets Assets	35918000
CY2019Q4	us-gaap	Assets Assets	132801000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1762000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4285000
CY2020Q4	sens	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	11674000
CY2019Q4	sens	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	18636000
CY2020Q4	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	3202000
CY2019Q4	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	43434000
CY2019Q4	us-gaap	Convertible Subordinated Debt Current ConvertibleSubordinatedDebtCurrent	60353000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16638000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	126708000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	57216000
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	11800000
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	62119000
CY2019Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	664000
CY2020Q4	sens	Long Term Options LongTermOptions	39734000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1483000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2278000
CY2020Q4	us-gaap	Liabilities Liabilities	177190000
CY2019Q4	us-gaap	Liabilities Liabilities	141450000
CY2019Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	3000
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	3000
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0
CY2020Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	2811000
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	2811000
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	265582688
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	203452812
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	266000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	203000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	504162000
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	464491000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-648511000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-473343000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-144083000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-8649000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35918000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	132801000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1368000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4924000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2039000
CY2020	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	3581000
CY2019	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	16377000
CY2018	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	16874000
CY2020	us-gaap	Revenues Revenues	4949000
CY2019	us-gaap	Revenues Revenues	21301000
CY2018	us-gaap	Revenues Revenues	18913000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	22315000
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	40749000
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	27059000
CY2020	us-gaap	Gross Profit GrossProfit	-17366000
CY2019	us-gaap	Gross Profit GrossProfit	-19448000
CY2018	us-gaap	Gross Profit GrossProfit	-8146000
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	20550000
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	49555000
CY2018	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	27730000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20413000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38430000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31863000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20801000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23229000
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19839000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-79130000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-130662000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-87578000
CY2020	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	175000
CY2019	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	1933000
CY2018	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	2001000
CY2020	sens	Nonoperating Gain Loss Fair Value Adjustment NonoperatingGainLossFairValueAdjustment	-30721000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-21112000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-398000
CY2020	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	12706000
CY2020	sens	Interest Expense Excluding Debt Issuance Costs InterestExpenseExcludingDebtIssuanceCosts	16167000
CY2019	sens	Interest Expense Excluding Debt Issuance Costs InterestExpenseExcludingDebtIssuanceCosts	11799000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.77
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-175168000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-115549000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-93971000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-175168000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-115549000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-93971000
CY2018	sens	Interest Expense Excluding Debt Issuance Costs InterestExpenseExcludingDebtIssuanceCosts	8282000
CY2020	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	1216000
CY2019	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	3344000
CY2020	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-11641000
CY2019	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	29232000
CY2018	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	209000
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2339000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-311000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-511000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-321000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-96038000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15113000
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6393000
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.60
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	227912358
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	188754160
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	157429145
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	7267000
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	149044000
CY2018	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2259000
CY2018	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	250000
CY2018	sens	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options And Restricted Stock Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsAndRestrictedStockRequisiteServicePeriodRecognition	6412000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-93971000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	71261000
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	26757000
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	108000
CY2019	sens	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options And Restricted Stock Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsAndRestrictedStockRequisiteServicePeriodRecognition	8052000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	722000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-115549000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-8649000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-26000
CY2020	sens	Exercise Of Stock Options Vesting Of Rs Us And Espp Purchases ExerciseOfStockOptionsVestingOfRSUsAndESPPPurchases	576000
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	27259000
CY2020	sens	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options And Restricted Stock Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsAndRestrictedStockRequisiteServicePeriodRecognition	7314000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	4611000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-175168000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-144083000
CY2020	us-gaap	Profit Loss ProfitLoss	-175168000
CY2019	us-gaap	Profit Loss ProfitLoss	-115549000
CY2018	us-gaap	Profit Loss ProfitLoss	-93971000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1141000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1001000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	270000
CY2020	sens	Amortization Of Financing Costs Discounts And Deferred Costs AmortizationOfFinancingCostsDiscountsAndDeferredCosts	10977000
CY2019	sens	Amortization Of Financing Costs Discounts And Deferred Costs AmortizationOfFinancingCostsDiscountsAndDeferredCosts	8457000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	8052000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	6412000
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	-4171000
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	3970000
CY2018	us-gaap	Inventory Write Down InventoryWriteDown	201000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3282000
CY2018	sens	Amortization Of Financing Costs Discounts And Deferred Costs AmortizationOfFinancingCostsDiscountsAndDeferredCosts	3317000
CY2020	sens	Fair Value Adjustment Derivative Liability FairValueAdjustmentDerivativeLiability	11641000
CY2019	sens	Fair Value Adjustment Derivative Liability FairValueAdjustmentDerivativeLiability	-29232000
CY2018	sens	Fair Value Adjustment Derivative Liability FairValueAdjustmentDerivativeLiability	-209000
CY2020	sens	Nonoperating Gain Loss Fair Value Adjustment NonoperatingGainLossFairValueAdjustment	-30721000
CY2020	sens	Gains Losses On Extinguishment Of Debt And Debt Modification Fees GainsLossesOnExtinguishmentOfDebtAndDebtModificationFees	-21112000
CY2019	sens	Gains Losses On Extinguishment Of Debt And Debt Modification Fees GainsLossesOnExtinguishmentOfDebtAndDebtModificationFees	-398000
CY2020	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	12706000
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2339000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	7314000
CY2018	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	115000
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-181000
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-310000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7393000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3715000
CY2020	sens	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-737000
CY2019	sens	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	527000
CY2018	sens	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	1893000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-15819000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10668000
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7441000
CY2020	sens	Increase Decrease In Deposit Assets And Other Assets IncreaseDecreaseInDepositAssetsAndOtherAssets	-117000
CY2019	sens	Increase Decrease In Deposit Assets And Other Assets IncreaseDecreaseInDepositAssetsAndOtherAssets	3442000
CY2018	sens	Increase Decrease In Deposit Assets And Other Assets IncreaseDecreaseInDepositAssetsAndOtherAssets	-59000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2522000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-122000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3395000
CY2020	sens	Increase Decrease In Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities	-6585000
CY2019	sens	Increase Decrease In Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities	4827000
CY2018	sens	Increase Decrease In Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities	8355000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-628000
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	628000
CY2020	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-379000
CY2019	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	388000
CY2018	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	710000
CY2020	sens	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-795000
CY2018	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-16000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-67422000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-136047000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-90771000
CY2020	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	181000
CY2019	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1045000
CY2018	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	989000
CY2018	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	28350000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-181000
CY2018	sens	Payments On Right Of Use Liability Building PaymentsOnRightOfUseLiabilityBuilding	7935000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1045000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19426000
CY2020	sens	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	-26000
CY2019	sens	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	26757000
CY2018	sens	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	149044000
CY2020	sens	Proceeds From Exercise Of Stock Options And Espp Purchase ProceedsFromExerciseOfStockOptionsAndESPPPurchase	576000
CY2019	sens	Proceeds From Exercise Of Stock Options And Espp Purchase ProceedsFromExerciseOfStockOptionsAndESPPPurchase	108000
CY2018	sens	Proceeds From Exercise Of Stock Options And Espp Purchase ProceedsFromExerciseOfStockOptionsAndESPPPurchase	2259000
CY2019	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	722000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-648500000
CY2020	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	55971000
CY2019	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	127000000
CY2018	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	52950000
CY2020	sens	Payments Of Notes Payable Issuance Costs PaymentsOfNotesPayableIssuanceCosts	601000
CY2019	sens	Payments Of Notes Payable Issuance Costs PaymentsOfNotesPayableIssuanceCosts	4301000
CY2018	sens	Payments Of Notes Payable Issuance Costs PaymentsOfNotesPayableIssuanceCosts	2245000
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2049000
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	66050000
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	15000000
CY2018	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	10000000
CY2019	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	37000000
CY2018	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	20000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-10130000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	96237000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	191988000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-77733000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-40855000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	120643000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95938000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	136793000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16150000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18205000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95938000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	136793000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	4726000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	5233000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	3136000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2974000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	32000
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	178000
CY2020	us-gaap	Stock Issued1 StockIssued1	227000
CY2020	sens	Proceeds From Issuance Of Common Stock And Warrants In Connection With Highbridge Transactions ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithHighbridgeTransactions	55303000
CY2020	sens	Proceeds From Issuance Of Common Stock In Connection With Energy Capital ProceedsFromIssuanceOfCommonStockInConnectionWithEnergyCapital	3399000
CY2020	us-gaap	Notes Reduction NotesReduction	24000000
CY2020	us-gaap	Notes Issued1 NotesIssued1	15675000
CY2020	us-gaap	Nature Of Operations NatureOfOperations	<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">Organization</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Senseonics Holdings, Inc., a Delaware corporation, is a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Senseonics, Incorporated is a wholly owned subsidiary of Senseonics Holdings and was originally incorporated on October 30, 1996 and commenced operations on January 15, 1997. Senseonics Holdings and Senseonics, Incorporated are hereinafter collectively referred to as the “Company” unless otherwise indicated or the context otherwise requires.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p>
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-175200000
CY2020	sens	Number Of Geographical Markets NumberOfGeographicalMarkets	2
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, recoverability of long-lived assets, deferred taxes and valuation allowances, derivative liabilities, obsolete inventory, warranty obligations, variable consideration related to revenue, depreciable lives of property and equipment, and accruals for clinical study costs, which are accrued based on estimates of work performed under contract. Actual results could differ from those estimates; however, management does not believe that such differences would be material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p>
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2020Q4	us-gaap	Cash Cash	18002000
CY2019Q4	us-gaap	Cash Cash	38043000
CY2020Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	3000
CY2019Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	37769000
CY2019Q4	us-gaap	Commercial Paper At Carrying Value CommercialPaperAtCarryingValue	13870000
CY2019Q4	us-gaap	Asset Backed Securities At Carrying Value AssetBackedSecuritiesAtCarryingValue	6256000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18005000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95938000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18005000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95938000
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	200000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18205000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95938000
CY2018	sens	Number Of Geographical Markets NumberOfGeographicalMarkets	2
CY2019	sens	Number Of Geographical Markets NumberOfGeographicalMarkets	2
CY2020	us-gaap	Derivatives Embedded Derivatives DerivativesEmbeddedDerivatives	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><b style="font-weight:bold;">Derivative Financial Instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt;">In connection with the Company’s issuance of the convertible senior subordinated notes due 2023 (the “2023 Notes”), in January 2018, the Company bifurcated the embedded conversion option, along with the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as a derivative liability in the Company’s consolidated balance sheets in accordance with Accounting Standards Codification (“ASC”) Topic 815, <i style="font-style:italic;">Derivatives and Hedging</i>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:10.0pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt;">In July 2019, the Company issued $82.0 million in aggregate principal amount of convertible senior subordinated notes due 2025 (the “2025 Notes). In connection with the 2025 Notes, the Company bifurcated the embedded conversion option along with the fundamental change make-whole provision and the cash settled fundamental make-whole shares provision, and recorded the fair value of these embedded features as a derivative liability in the Company’s consolidated balance sheets in accordance with ASC Topic 815, <i style="font-style:italic;">Derivatives and Hedging</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:10.0pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:36pt;margin:0pt;">On April 21, 2020, the Company entered into the Highbridge Loan Agreement, in which an aggregate principal amount of $15.0 million was borrowed through the issuance and sale of the First Lien Notes and issued 1,500,000 shares of our common stock to the Lenders as a commitment fee. The First Lien Notes also contained redemption features that were evaluated for bifurcation as separate derivative instruments including the permitted prepayment put option, the mandatory accelerated redemption and the mandatory redemption and reinvestment upon an asset sale. We recorded the fair value of the embedded features in the amount of $1.0 million as a debt premium and derivative asset in our consolidated balance sheets in accordance with ASC Topic 815, Derivatives and Hedging. The derivative was adjusted to fair value at each reporting period, with the change recorded in change in fair value of derivatives that is a component of other income (expense) in our consolidated statements of operations and comprehensive loss. On August 14, 2020, the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="white-space:pre-wrap;">Company prepaid the First Lien Notes in full, including the discounted prepayment premium, in the amount of approximately $17.6 million and recognized a loss on extinguishment in the amount of $0.7 million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:36pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:36pt;margin:0pt;">On April 21, 2020, the Company entered into a Note Purchase and Exchange Agreement with certain funds managed by Highbridge providing for the exchange (the “Exchange”) of $24.0 million aggregate principal amount of the outstanding 2025 Notes for (i) $15.7 million aggregate principal amount of newly issued Second Lien Notes, (ii) 11,026,086 shares of common stock, (iii) warrants to purchase up to 4,500,000 shares of common stock at an exercise price of $0.66 per share, and (iv) $0.3 million in accrued and unpaid interest on the 2025 Notes being exchanged. On August 9, 2020, we entered into a First Amendment to Note Purchase and Exchange Agreement with Highbridge (as amended by the Amendment, the “Exchange Agreement”). The Second Lien Notes also contain redemption features that were evaluated for bifurcation as separate derivative instruments including the permitted prepayment put option, the mandatory accelerated redemption and the mandatory redemption and reinvestment upon an asset sale. Unlike the First Lien Notes, the Second Lien Notes also permit voluntary conversion at the option of the holder as described above. We recorded the fair value of these embedded features in the amount of $1.9 million as a derivative asset in our consolidated balance sheets in accordance with ASC Topic 815, Derivatives and Hedging. The derivative is adjusted to fair value at each reporting period, with the change in the fair value recorded in change in fair value of derivatives that is a component of other income (expense) in our consolidated statement of operations and comprehensive loss. During the fiscal year ended December 31, 2020, Highbridge elected to convert the full $15.7 million of outstanding principal on the Second Lien Notes for issuance of 42,776,936 shares of common stock, which included prepayment premiums and were based off of our election of PIK interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:10.0pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt;">In August 2020, the Company issued $35.0 million in aggregate principal amount of convertible senior secured notes due PHC, or the PHC Notes. The Note Purchase Agreement also contained several provisions requiring bifurcation as a separate derivative liability including an embedded conversion feature, mandatory prepayment upon event of default that constitutes a breach of the minimum revenue financial covenant, optional redemption upon an event of default, change in interest rate after PMA approval and default interest upon an event of default. The Company recorded the fair value of the embedded features in the amount of $25.8 million as a derivative liability in the Company’s consolidated balance sheets in accordance with ASC Topic 815, Derivatives and Hedging.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:10.0pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt;">The financial instruments above are remeasured at the end of each reporting period with changes in fair value recorded in the consolidated statements of operations and comprehensive loss in other income (expense) as a change in fair value of the derivative liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p>
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1102000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	754000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1557000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2001000
CY2020	us-gaap	Depreciation Depreciation	400000
CY2019	us-gaap	Depreciation Depreciation	500000
CY2018	us-gaap	Depreciation Depreciation	300000
CY2020	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	300000
CY2019	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	1400000
CY2020	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Warranty Obligation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company provides a warranty of one year on its smart transmitters. Additionally, the Company may also replace Eversense system components that do not function in accordance with the product specifications. Estimated replacement costs are recorded at the time of shipment as a charge to cost of sales in the consolidated statement of operations and are developed by analyzing product performance data and historical replacement experience, including comparing actual return management authorizations to revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">At December 31, 2020 and December 31, 2019, the warranty reserve was $0.6 million and $2.2 million, respectively. The following table provides a reconciliation of the change in estimated warranty liabilities for the years ended December 31, 2020 and 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:10.0pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:64.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;"></span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at beginning of the year</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,197</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 816</p></td></tr><tr><td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for warranties during the period</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (266)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,296</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Settlements made during the period</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,285)</p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,915)</p></td></tr><tr><td style="vertical-align:bottom;width:64.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at end of the year</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 646</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,197</p></td></tr></table>
CY2020	sens	Product Warranty Term ProductWarrantyTerm	P1Y
CY2020Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	600000
CY2019Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	2200000
CY2019Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	2197000
CY2018Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	816000
CY2020	sens	Standard Product Warranty Provision Reduction StandardProductWarrantyProvisionReduction	266000
CY2019	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	3296000
CY2020	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	1285000
CY2019	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	1915000
CY2020Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	646000
CY2019Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	2197000
CY2020	sens	Payment Period PaymentPeriod	P60D
CY2020	sens	Patient Fee Basis To Determine Customer Reimbursement PatientFeeBasisToDetermineCustomerReimbursement	99
CY2020	sens	Product Warranty Term ProductWarrantyTerm	P1Y
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	173222308
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	99653576
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	46010165
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	203000
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3944000
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2626000
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	10938000
CY2020Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	2452000
CY2019Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	2047000
CY2020Q4	us-gaap	Inventory Net InventoryNet	5281000
CY2019Q4	us-gaap	Inventory Net InventoryNet	16929000
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	57700000
CY2020Q4	sens	Prepaid Contract Manufacturing Current PrepaidContractManufacturingCurrent	3324000
CY2019Q4	sens	Prepaid Contract Manufacturing Current PrepaidContractManufacturingCurrent	3043000
CY2020Q4	sens	Prepaid Information Technology And Software Costs Current PrepaidInformationTechnologyAndSoftwareCostsCurrent	150000
CY2019Q4	sens	Prepaid Information Technology And Software Costs Current PrepaidInformationTechnologyAndSoftwareCostsCurrent	294000
CY2020Q4	us-gaap	Prepaid Rent PrepaidRent	102000
CY2020Q4	sens	Consulting Consulting	84000
CY2020Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	53000
CY2019Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	605000
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	50000
CY2019Q4	us-gaap	Prepaid Insurance PrepaidInsurance	44000
CY2020Q4	sens	Prepaid Clinical And Preclinical Costs PrepaidClinicalAndPreclinicalCosts	11000
CY2019Q4	sens	Prepaid Clinical And Preclinical Costs PrepaidClinicalAndPreclinicalCosts	240000
CY2019Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	107000
CY2019Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	179000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3774000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4512000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2659000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2755000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4344000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5630000
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1773000
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2153000
CY2020Q4	sens	Accrued Contract Manufacturing Costs Current AccruedContractManufacturingCostsCurrent	1421000
CY2019Q4	sens	Accrued Contract Manufacturing Costs Current AccruedContractManufacturingCostsCurrent	2452000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	880000
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1384000
CY2020Q4	sens	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	842000
CY2019Q4	sens	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	1956000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	794000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	696000
CY2020Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	646000
CY2019Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	2197000
CY2020Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	615000
CY2019Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	553000
CY2020Q4	sens	Accrued Patient Access And Incentive Programs Current AccruedPatientAccessAndIncentiveProgramsCurrent	208000
CY2019Q4	sens	Accrued Patient Access And Incentive Programs Current AccruedPatientAccessAndIncentiveProgramsCurrent	1578000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	151000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	37000
CY2020Q4	sens	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	11674000
CY2019Q4	sens	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	18636000
CY2020	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2100000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2300000
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	3202000
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2561000
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	15700000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	900000
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000
CY2018	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2128000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	794000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1483000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2277000
CY2020	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	7564000
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	8433000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	969000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1002000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	600000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2571000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	294000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2277000
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	36312000
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.091
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.091
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	900000
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	100000
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000
CY2018	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000
CY2020Q3	sens	Number Of Voting Classes NumberOfVotingClasses	1
CY2020Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	4800000
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	212000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-21112000
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	37321000
CY2019	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	6823000
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4976000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-398000
CY2019	us-gaap	Interest Expense Debt InterestExpenseDebt	12197000
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	115475000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.33
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.60
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	265582688
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	203452812
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	3000
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21458000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.61
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	9294000
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.54
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	88000
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.26
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	6446000
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.48
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	24218000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.16
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M20D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	469000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.54
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	201000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.53
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	8711000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.95
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15775000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M3D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	15775000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.27
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	12222000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.19
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M6D
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.91
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	201447
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	87591
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1438671
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3700000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	5800000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	8200000
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	700000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	800000
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.59
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.64
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.58
CY2020	sens	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue	0.33
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	1.61
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7254000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8052000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6375000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	115531000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	94630000
CY2020Q4	sens	Deferred Tax Assets Capitalized Start Up Costs DeferredTaxAssetsCapitalizedStartUpCosts	8477000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	9405000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4056000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2978000
CY2020Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	9222000
CY2019Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	5916000
CY2020Q4	sens	Deferred Tax Liability Amortization Right Of Use Asset DeferredTaxLiabilityAmortizationRightOfUseAsset	477000
CY2019Q4	sens	Deferred Tax Liability Amortization Right Of Use Asset DeferredTaxLiabilityAmortizationRightOfUseAsset	637000
CY2020Q4	sens	Deferred Tax Liability Amortization Of Debt Discount DeferredTaxLiabilityAmortizationOfDebtDiscount	12082000
CY2019Q4	sens	Deferred Tax Liability Amortization Of Debt Discount DeferredTaxLiabilityAmortizationOfDebtDiscount	10971000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	12559000
CY2019Q4	sens	Deferred Tax Assets Capitalized Start Up Costs DeferredTaxAssetsCapitalizedStartUpCosts	9353000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	10208000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1096000
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2495000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	148590000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	124777000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	136031000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	113169000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	12559000
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11608000
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	11608000
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	22800000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	24000000.0
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	515240000
CY2020Q4	sens	Operating Loss Carryforwards Subject To Expiry OperatingLossCarryforwardsSubjectToExpiry	198700000
CY2020	sens	Income Tax Expense Benefit Continuing Operations Share Based Compensation IncomeTaxExpenseBenefitContinuingOperationsShareBasedCompensation	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0232
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0157
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0227
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0046
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0132
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0127
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0085
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0217
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.1064
CY2020	sens	Effective Income Tax Rate Reconciliation Nondeductible Expense Debt And Other Issuance Cost Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtAndOtherIssuanceCostPercent	-0.1115
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.0044
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.0091
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.0039
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1134
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2081
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1351
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2351000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1969000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1670000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	201000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	396000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	323000
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	14000
CY2018	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	24000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2552000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2351000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1969000
CY2019Q2	us-gaap	Gross Profit GrossProfit	-4553000
CY2019Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2020Q1	us-gaap	Revenues Revenues	36000
CY2020Q2	us-gaap	Revenues Revenues	261000
CY2020Q3	us-gaap	Revenues Revenues	767000
CY2020Q4	us-gaap	Revenues Revenues	3885000
CY2020Q1	us-gaap	Gross Profit GrossProfit	-19634000
CY2020Q2	us-gaap	Gross Profit GrossProfit	-1143000
CY2020Q3	us-gaap	Gross Profit GrossProfit	835000
CY2020Q4	us-gaap	Gross Profit GrossProfit	2576000
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	24197000
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	11383000
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	13303000
CY2020Q4	us-gaap	Operating Expenses OperatingExpenses	12882000
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-43831000
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-12526000
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12468000
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-10306000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-42593000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-7515000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-23428000
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-101632000
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2020Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2019Q1	us-gaap	Revenues Revenues	3423000
CY2019Q2	us-gaap	Revenues Revenues	4607000
CY2019Q3	us-gaap	Revenues Revenues	4319000
CY2019Q4	us-gaap	Revenues Revenues	8953000
CY2019Q1	us-gaap	Gross Profit GrossProfit	-3310000
CY2019Q3	us-gaap	Gross Profit GrossProfit	-3340000
CY2019Q4	us-gaap	Gross Profit GrossProfit	-8244000
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	26458000
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	30100000
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	28024000
CY2019Q4	us-gaap	Operating Expenses OperatingExpenses	26632000
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-29768000
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-34653000
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-31364000
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-34877000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-29365000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-31074000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-19499000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-35611000
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18

Files In Submission

Name	View Source	Status
0001558370-21-002458-index-headers.html	Edgar Link	pending
0001558370-21-002458-index.html	Edgar Link	pending
0001558370-21-002458.txt	Edgar Link	pending
0001558370-21-002458-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sens-20201231.xsd	Edgar Link	pending
sens-20201231x10k.htm	Edgar Link	pending
sens-20201231x10k004.jpg	Edgar Link	pending
sens-20201231x10k005.jpg	Edgar Link	pending
sens-20201231x10k_htm.xml	Edgar Link	completed
sens-20201231xex23d1.htm	Edgar Link	pending
sens-20201231xex31d1.htm	Edgar Link	pending
sens-20201231xex31d2.htm	Edgar Link	pending
sens-20201231xex32d1.htm	Edgar Link	pending
sens-20201231xex3d7.htm	Edgar Link	pending
sens-20201231xex3d7002.jpg	Edgar Link	pending
sens-20201231_cal.xml	Edgar Link	unprocessable
sens-20201231_def.xml	Edgar Link	unprocessable
sens-20201231_lab.xml	Edgar Link	unprocessable
sens-20201231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SENS
Senseonics Holdings, Inc. Stock $sens

2020 Q4 Form 10-K Financial Statement

#000155837021002458 Filed on March 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SENS Senseonics Holdings, Inc. Stock $sens

2020 Q4 Form 10-K Financial Statement

#000155837021002458 Filed on March 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SENS
Senseonics Holdings, Inc. Stock $sens